A landmark UK Biobank study integrates genomics with lipid and inflammatory markers to predict coronary artery disease (CAD) risk more accurately in midlife.
Four-Biomarker Model
The approach combines coronary artery disease polygenic risk score (CAD PRS)—calculated from DNA analysis of hundreds of common genetic variants via blood, saliva, or cheek swab—LDL cholesterol (LDL-C), lipoprotein(a) (Lp(a)), and high-sensitivity C-reactive protein (hsCRP). In 215,695 adults aged 40-69 followed for 12 years, each elevated biomarker independently raised CAD hazard ratios: CAD PRS (1.79), LDL-C (1.60), Lp(a) (1.20), hsCRP (1.64). All four elevated together increased risk 4.65-fold.[pmc.ncbi.nlm.nih]
Age and Sex Effects
Associations were stronger in younger individuals across all markers (P<0.0001) and for CAD PRS in men (HR 1.49 per SD) versus women (1.37; P-interaction ≤0.001). The model achieved a C-statistic of 0.753, surpassing pooled cohort equations (0.740), with 32% improved net reclassification.
Clinical Implications
A single midlife panel outperforms traditional calculators, especially for early prevention in younger adults. CAD PRS testing ($255 via Mass General Brigham) provides a one-time genetic snapshot in 3-4 weeks to triage high-risk patients for statins, Lp(a) therapies, or CCTA.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.